Search results for " pulmonary"

showing 10 items of 517 documents

COPD at the end of life: Predictors of the emotional distress of patients and their family caregivers.

2020

BackgroundFew studies have focused on patients' emotional distress with end-stage chronic obstructive pulmonary disease (COPD) and their main family caregivers.MethodsCross-sectional data about emotional, functional, and burden-related variables were collected from 85 patients with end-stage COPD and their 85 respective main family caregivers to determine the variables that could predict their emotional well-being. Descriptive analyses, comparison of means, hierarchical regression models, and comparative quali-quantitative analyses were carried out.ResultsData show that the great majority of patients with COPD spend years with this diagnosis, and have been admitted to the hospital several t…

MalePulmonologyCross-sectional studyEmotionsSocial SciencesDiseaseComorbidityAnxietyPsychological DistressSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineCost of IllnessSurveys and QuestionnairesMedicine and Health SciencesPsychology030212 general & internal medicineYoung adultAged 80 and overMultidisciplinaryFamily caregiversDepressionQRMiddle AgedHospitalsDeathDistressCaregivers030220 oncology & carcinogenesisMedicineAnxietyFemalemedicine.symptomClinical psychologyResearch ArticleAdultPatientsScienceChronic Obstructive Pulmonary Disease03 medical and health sciencesYoung AdultSeverity of illnessMental Health and PsychiatrymedicineHumansAgedbusiness.industryMood DisordersBiology and Life Sciencesmedicine.diseaseComorbidityHealth CareCross-Sectional StudiesHealth Care FacilitiesbusinessPloS one
researchProduct

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

2017

Background The risk and outcomes of stroke in patients with chronic obstructive pulmonary disease exacerbations (COPDe) remain unclear. We examined whether patients with COPDe faced increased risk of stroke or post-stroke outcomes. Methods Using Taiwan’s National Health Insurance Research Database, we identified 1918 adults with COPDe and selected comparison cohorts of 3836 adults with COPD no exacerbations and 7672 adults without COPD who were frequency matched by age and sex in 2000–2008 (Study 1). Stroke event was identified during 2000–2013 follow-up period. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of stroke associated with COPDe were calculated. In a nested cohor…

MalePulmonologyEconomicslcsh:MedicineSocial SciencesComorbidityVascular MedicinePulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMedicine and Health SciencesOdds Ratio030212 general & internal medicinelcsh:ScienceStrokeAged 80 and overCOPDMultidisciplinaryHazard ratioMiddle AgedStrokeHospitalizationNeurologyResearch DesignPopulation SurveillanceDisease ProgressionFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignChronic Obstructive Pulmonary DiseaseCerebrovascular DiseasesCardiologyTaiwanResearch and Analysis MethodsRisk Assessment03 medical and health sciencesHealth EconomicsInternal medicinemedicineHumansIntensive care medicineAdverse effectIschemic StrokeAgedRetrospective StudiesEpilepsybusiness.industrylcsh:RRetrospective cohort studyOdds ratioPneumoniamedicine.diseaseComorbidityrespiratory tract diseasesHealth CarePatient Outcome Assessment030228 respiratory systemlcsh:QAdverse EventsbusinessHealth InsurancePLoS ONE
researchProduct

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) comp…

2019

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and C…

MalePulmonologyNeutrophilsPhysiologyAnti-Inflammatory AgentsPharmacologyPathology and Laboratory MedicineBiochemistryPulmonary Disease Chronic ObstructiveWhite Blood CellsGlucocorticoid receptorAnimal CellsMuscarinic acetylcholine receptorMedicine and Health SciencesPost-Translational ModificationPhosphorylationReceptorImmune ResponseMultidisciplinaryPharmaceuticsQRDrug SynergismMiddle AgedReceptors MuscarinicHealthy VolunteersBody FluidsChemistryBloodPhysical SciencesQuinolinesMedicineDrug Therapy CombinationFemalemedicine.symptomCellular TypesAnatomymedicine.drugResearch ArticleSignal TransductionAgonistTransmembrane Receptorsmedicine.drug_classp38 mitogen-activated protein kinasesChronic Obstructive Pulmonary DiseaseImmune CellsScienceImmunologyInflammationMuscarinic AntagonistsThiophenesFluticasone propionateSigns and SymptomsDrug TherapyCyclohexanesDiagnostic MedicinemedicineHumansAdrenergic beta-2 Receptor AgonistsAgedInflammationBlood CellsDose-Response Relationship Drugbusiness.industryAntagonistChemical CompoundsBiology and Life SciencesProteinsCell BiologyAcetylcholine ReceptorsFluticasoneMuscarinic Acetylcholine ReceptorsReceptors Adrenergic beta-2PropionatesbusinessReceptor Antagonist TherapyPLoS ONE
researchProduct

The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study.

2019

BackgroundThis paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional phenotype, based on a multidimensional assessment; (ii) describe the identified multi-dimensional phenotypes.MethodsAn exploratory factor analysis to identify the main classificatory variables and, then, a cluster analysis based on these variables were run to classify the COPD-diagnosed 514 patients enrolled in the STORICO (trial registration number: NCT03105999) study into multi-dimensional phenotypes.ResultsThe circadian rhythm of symptoms and health-related quality of life, but neither comorbidity nor respiratory function, qualified as primary classificatory variables. Five multidimension…

MalePulmonologyPhysiologyComorbidityAnxietyPathology and Laboratory MedicineCohort StudiesPulmonary Disease Chronic ObstructiveMathematical and Statistical TechniquesQuality of lifeMedicine and Health SciencesCoughingCluster AnalysisRespiratory functionPublic and Occupational HealthAged 80 and overCOPDMultidisciplinaryDepressionApplied MathematicsSimulation and ModelingQStatisticsRMiddle AgedExploratory factor analysisCircadian RhythmBody FluidsCircadian RhythmsPhenotypeItalyPhysical SciencesAnxietyMedicineFemalemedicine.symptomAnatomyFactor AnalysisAlgorithmsCohort studyResearch Articlemedicine.medical_specialtyScienceMemory EpisodicChronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch and Analysis MethodsClustering AlgorithmsSigns and SymptomsDiagnostic MedicineInternal medicinemedicineCOPDHumansStatistical MethodsAgedbusiness.industryBiology and Life SciencesPhysical Activitymedicine.diseaseComorbidityrespiratory tract diseasesMucusDyspneaCoughQuality of LifeObservational studybusinessFactor Analysis StatisticalSleepPhysiological ProcessesChronobiologymultiple phenotypesMathematicsPloS one
researchProduct

Mechanical strain causes adaptive change in bronchial fibroblasts enhancing profibrotic and inflammatory responses

2016

Asthma is characterized by periodic episodes of bronchoconstriction and reversible airway obstruction; these symptoms are attributable to a number of factors including increased mass and reactivity of bronchial smooth muscle and extracellular matrix (ECM) in asthmatic airways. Literature has suggested changes in cell responses and signaling can be elicited via modulation of mechanical stress acting upon them, potentially affecting the microenvironment of the cell. In this study, we hypothesized that mechanical strain directly affects the (myo)fibroblast phenotype in asthma. Therefore, we characterized responses of bronchial fibroblasts, from 6 normal and 11 asthmatic non-smoking volunteers,…

MalePulmonologyPulmonary FibrosisAdult; Asthma; Biomechanical Phenomena; Bronchi; Case-Control Studies; Female; Fibroblasts; Humans; Male; Pneumonia; Pulmonary Fibrosis; Stress Mechanical; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Glycobiologylcsh:MedicinePathology and Laboratory MedicineBiochemistryAnimal CellsMedicine and Health Scienceslcsh:ScienceImmune ResponseMusculoskeletal SystemConnective Tissue CellsSmooth MusclesMusclesMedicine (all)Extracellular MatrixBiomechanical PhenomenaConnective TissueFibroblastProteoglycansFemaleCellular TypesAnatomyCellular Structures and OrganellesCase-Control StudieResearch ArticleHumanAdultPulmonary FibrosiImmunologyBronchiSigns and SymptomsExtraction techniquesDiagnostic MedicineHumansInflammationBiochemistry Genetics and Molecular Biology (all)Settore BIO/16 - Anatomia Umanalcsh:RBiology and Life SciencesProteinsCell BiologyPneumoniaFibroblastsRNA extractionAsthmaResearch and analysis methodsBiological TissueAgricultural and Biological Sciences (all)Case-Control Studieslcsh:QStress MechanicalCollagens
researchProduct

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20…

2020

Artículo con numerosos autores. Sólo se hace referencia al primero que coincide con el de la UAM y al colectivo

MaleRespiratory diseasesRespiratory Tract DiseasesDiseaseChronic respiratory diseasesGlobal Burden of DiseasePulmonary Disease Chronic Obstructive0302 clinical medicineCost of Illness11. SustainabilityMETABOLIC RISKSEPIDEMIOLOGY030212 general & internal medicineChildCause of deathAged 80 and overCOPDDALYChronic obstructive pulmonary diseaseMortality rateRespiratory disease1. No povertyAge FactorsMiddle AgedDeath causes3. Good healthPREVALENCEHealth risksChild PreschoolCOMPARATIVE RISK-ASSESSMENTFemaledeath and disability worldwideQuality-Adjusted Life YearsTERRITORIESBURDENgrowth in absolute numbersPulmonary and Respiratory MedicineAdultADJUSTED LIFE-YEARSHealth burdensAdolescentMedicina195 COUNTRIESchronic respiratory diseasesArticle1117 Public Health and Health Services03 medical and health sciencesYoung AdultLife ExpectancySex FactorsBurden of Disease Respiratory diseaseSarcoidosis PulmonaryEnvironmental healthmedicineDisability-adjusted life yearHumansCOPDEXPOSURERisk factorMortalityAgedper-capita basisbusiness.industryDISABILITYInfant NewbornInfant1103 Clinical Sciencesasthmamedicine.diseaseAsthmaYears of potential life lost030228 respiratory systemRisk factors13. Climate actionSystematic analysesChronic DiseaseINJURIESHuman medicinePneumoconiosisMorbiditybusinessLung Diseases Interstitial1199 Other Medical and Health Sciences
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis.

2011

BackgroundIt is increasingly clear that some heat shock proteins (Hsps) play a role in inflammation. Here, we report results showing participation of Hsp60 in the pathogenesis of chronic obstructive pulmonary diseases (COPD), as indicated by data from both in vivo and in vitro analyses.Methods and resultsBronchial biopsies from patients with stable COPD, smoker controls with normal lung function, and non-smoker controls were studied. We quantified by immunohistochemistry levels of Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, and HSF-1, along with levels of inflammatory markers. Hsp10, Hsp40, and Hsp60 were increased during progression of disease. We found also a positive correlation between th…

MaleSTRESSPulmonologyChronic Obstructive Pulmonary DiseasesNeutrophilsBiopsyGene ExpressionCD8-Positive T-Lymphocytesmedicine.disease_causeBiochemistryEpitheliumPulmonary function testingPathogenesisACTIVATIONPulmonary Disease Chronic ObstructiveMolecular Cell BiologyLungCOPDMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionCOPD Hsp60QRCOPD heat shock proteins inflammationMiddle AgedImmunohistochemistrymedicine.anatomical_structureEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISMedicineFemalemedicine.symptomInflammation MediatorsSPINAL-CORDResearch ArticleEXPRESSIONanimal structuresCOPD; heat shock proteins; inflammationScienceImmunologyMolecular Sequence DataInflammationBronchichemical and pharmacologic phenomenaHEAT-SHOCK-PROTEIN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS ACUTE LUNG INJURY SPINAL-CORD CELL-DEATH KAPPA-B HEAT-SHOCK-PROTEIN-60 STRESS EXPRESSION ACTIVATIONKAPPA-BBiologyHEAT-SHOCK-PROTEINMicrobiologycomplex mixturesCell LineACUTE LUNG INJURYMolecular GeneticsIn vivoStress PhysiologicalHeat shock proteinmedicineGeneticsHumansCOPDRNA MessengerBiologyAgedLungMucous MembraneBase SequenceSettore BIO/16 - Anatomia UmanaMacrophagesfungiImmunityTranscription Factor RelAProteinsComputational BiologyChaperonin 60medicine.diseaseChaperone Proteinsrespiratory tract diseasesGene Expression RegulationCELL-DEATHHEAT-SHOCK-PROTEIN-60inflammationImmunologyheat shock proteinsClinical ImmunologyOxidative stressBiomarkers
researchProduct

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

2018

Chronic obstructive pulmonary disease (COPD) increases the risk of mortality in non-valvular atrial fibrillation (NVAF) patients. Data on the relationship of COPD to major cardiovascular events (MACE) in AF have not been defined. The aim of the study is to assess the predictive value of COPD on incident MACE in NVAF patients over a 3-year follow-up. In the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) cohort, we evaluate the impact of COPD on the following clinical endpoints: MACE (including vascular death, fatal/non-fatal MI and stroke/TIA), cardiovascular (CV) death and all-cause mortality. Among 2027 NVAF patients, pati…

MaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologyPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMajor cardiovascular eventCause of DeathRisk of mortalityPrevalenceMedicine030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyStrokeCause of deathCOPDChronic obstructive pulmonary diseaseIncidenceHazard ratioAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk Factors; Internal Medicine; Emergency MedicineAtrial fibrillationAtrial fibrillation Cardiovascular mortality Chronic obstructive pulmonary disease Major cardiovascular eventsItalyCardiovascular DiseasesCardiologyEmergency MedicineFemaleSettore SECS-S/01 - Statisticamedicine.medical_specialtyChronic ObstructiveCardiovascular mortalityEndpoint DeterminationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk FactorsSocio-culturalePulmonary Disease03 medical and health sciencesPredictive Value of TestsInternal medicineInternal MedicineHumanscardiovascular diseasesAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular eventsAgedbusiness.industryMajor cardiovascular eventsmedicine.diseaseAtrial fibrillationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Internal Medicine; Emergency MedicinebusinessMaceFollow-Up Studies
researchProduct

Assessing biomarkers in a real-world severe asthma study (ARIETTA)

2016

AbstractThe prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication are to be included. In this real-world study, patients will be treated according to the…

MaleSevere asthmaCardiac & Cardiovascular SystemsExacerbationAIRWAY INFLAMMATIONRespiratory SystemEosinophilSeverity of Illness Indexlaw.inventionDOUBLE-BLIND0302 clinical medicineQuality of lifeRandomized controlled trialAdrenal Cortex HormoneslawForced Expiratory VolumeProspective Studies030212 general & internal medicineProspective cohort studyFluticasoneEPITHELIAL-CELLSExacerbationRANDOMIZED CONTROLLED-TRIALPrognosis3. Good healthTO-SEVERE ASTHMAFemaleLife Sciences & Biomedicinemedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPHENOTYPESNitric Oxide1102 Cardiovascular Medicine And HaematologyFluticasone propionate03 medical and health sciencesPredictive Value of TestsAdministration InhalationSeverity of illnessmedicineHumansNITRIC-OXIDE SYNTHASEIntensive care medicineCOMBINATIONAsthmaScience & Technologybusiness.industryPULMONARY-FUNCTION1103 Clinical SciencesBiomarkerImmunoglobulin Emedicine.diseaseAsthmarespiratory tract diseasesEosinophilsBiomarker; Eosinophil; Exacerbation; Periostin; Severe asthma; Pulmonary and Respiratory MedicinePeriostin030228 respiratory systemQuality of LifeCardiovascular System & CardiologyFluticasonebusinessCell Adhesion MoleculesBiomarkersRespiratory Medicine
researchProduct